Development of outcome measures for large-vessel vasculitis for use in clinical trials: Opportunities, challenges, and research agenda

Haner Direskeneli, Sibel Z. Aydin, Tanaz A. Kermani, Eric L. Matteson, Maarten Boers, Karen Herlyn, Raashid A. Luqmani, Tuhina Neogi, Philip Seo, Ravi Suppiah, Gunnar Tomasson, Peter A. Merkel

Research output: Contribution to journalArticle

Abstract

Giant cell (GCA) and Takayasu's arteritis (TAK) are 2 forms of large-vessel vasculitis (LVV) that involve the aorta and its major branches. GCA has a predilection for the cranial branches, while TAK tends to affect the extracranial branches. Both disorders may also cause nonspecific constitutional symptoms. Although some clinical features are more common in one or the other disorder and the ages of initial presentation differ substantially, there is enough clinical and histopathologic overlap between these disorders that some investigators suggest GCA and TAK may be 2 processes within the spectrum of a single disease. There have been few randomized therapeutic trials completed in GCA, and none in TAK. The lack of therapeutic trials in LVV is only partially explained by the rarity of these diseases. It is likely that the lack of well validated outcome measures for LVV and uncertainties regarding trial design contribute to the paucity of trials for these diseases. An initiative to develop a core set of outcome measures for use in clinical trials of LVV was launched by the international OMERACT Vasculitis Working Group in 2009 and subsequently endorsed by the OMERACT community at the OMERACT 10 meeting. Aims of this initiative include: (1) to review the literature and existing data related to outcome assessments in LVV; (2) to obtain the opinion of experts and patients on disease content; and (3) to formulate a research agenda to facilitate a more data-based approach to outcomes development. The Journal of Rheumatology

Original languageEnglish (US)
Pages (from-to)1471-1479
Number of pages9
JournalJournal of Rheumatology
Volume38
Issue number7
DOIs
StatePublished - Jul 2011

Fingerprint

Vasculitis
Takayasu Arteritis
Outcome Assessment (Health Care)
Clinical Trials
Research
Giant Cell Arteritis
Expert Testimony
Rheumatology
Uncertainty
Aorta
Research Personnel
Therapeutics

Keywords

  • Giant cell arteritis
  • Outcomes
  • Takayasu's arteritis
  • Vasculitis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Direskeneli, H., Aydin, S. Z., Kermani, T. A., Matteson, E. L., Boers, M., Herlyn, K., ... Merkel, P. A. (2011). Development of outcome measures for large-vessel vasculitis for use in clinical trials: Opportunities, challenges, and research agenda. Journal of Rheumatology, 38(7), 1471-1479. https://doi.org/10.3899/jrheum.110275

Development of outcome measures for large-vessel vasculitis for use in clinical trials : Opportunities, challenges, and research agenda. / Direskeneli, Haner; Aydin, Sibel Z.; Kermani, Tanaz A.; Matteson, Eric L.; Boers, Maarten; Herlyn, Karen; Luqmani, Raashid A.; Neogi, Tuhina; Seo, Philip; Suppiah, Ravi; Tomasson, Gunnar; Merkel, Peter A.

In: Journal of Rheumatology, Vol. 38, No. 7, 07.2011, p. 1471-1479.

Research output: Contribution to journalArticle

Direskeneli, H, Aydin, SZ, Kermani, TA, Matteson, EL, Boers, M, Herlyn, K, Luqmani, RA, Neogi, T, Seo, P, Suppiah, R, Tomasson, G & Merkel, PA 2011, 'Development of outcome measures for large-vessel vasculitis for use in clinical trials: Opportunities, challenges, and research agenda', Journal of Rheumatology, vol. 38, no. 7, pp. 1471-1479. https://doi.org/10.3899/jrheum.110275
Direskeneli, Haner ; Aydin, Sibel Z. ; Kermani, Tanaz A. ; Matteson, Eric L. ; Boers, Maarten ; Herlyn, Karen ; Luqmani, Raashid A. ; Neogi, Tuhina ; Seo, Philip ; Suppiah, Ravi ; Tomasson, Gunnar ; Merkel, Peter A. / Development of outcome measures for large-vessel vasculitis for use in clinical trials : Opportunities, challenges, and research agenda. In: Journal of Rheumatology. 2011 ; Vol. 38, No. 7. pp. 1471-1479.
@article{9a73dbf7ea6c434aa6c99c17934d52f3,
title = "Development of outcome measures for large-vessel vasculitis for use in clinical trials: Opportunities, challenges, and research agenda",
abstract = "Giant cell (GCA) and Takayasu's arteritis (TAK) are 2 forms of large-vessel vasculitis (LVV) that involve the aorta and its major branches. GCA has a predilection for the cranial branches, while TAK tends to affect the extracranial branches. Both disorders may also cause nonspecific constitutional symptoms. Although some clinical features are more common in one or the other disorder and the ages of initial presentation differ substantially, there is enough clinical and histopathologic overlap between these disorders that some investigators suggest GCA and TAK may be 2 processes within the spectrum of a single disease. There have been few randomized therapeutic trials completed in GCA, and none in TAK. The lack of therapeutic trials in LVV is only partially explained by the rarity of these diseases. It is likely that the lack of well validated outcome measures for LVV and uncertainties regarding trial design contribute to the paucity of trials for these diseases. An initiative to develop a core set of outcome measures for use in clinical trials of LVV was launched by the international OMERACT Vasculitis Working Group in 2009 and subsequently endorsed by the OMERACT community at the OMERACT 10 meeting. Aims of this initiative include: (1) to review the literature and existing data related to outcome assessments in LVV; (2) to obtain the opinion of experts and patients on disease content; and (3) to formulate a research agenda to facilitate a more data-based approach to outcomes development. The Journal of Rheumatology",
keywords = "Giant cell arteritis, Outcomes, Takayasu's arteritis, Vasculitis",
author = "Haner Direskeneli and Aydin, {Sibel Z.} and Kermani, {Tanaz A.} and Matteson, {Eric L.} and Maarten Boers and Karen Herlyn and Luqmani, {Raashid A.} and Tuhina Neogi and Philip Seo and Ravi Suppiah and Gunnar Tomasson and Merkel, {Peter A.}",
year = "2011",
month = "7",
doi = "10.3899/jrheum.110275",
language = "English (US)",
volume = "38",
pages = "1471--1479",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "7",

}

TY - JOUR

T1 - Development of outcome measures for large-vessel vasculitis for use in clinical trials

T2 - Opportunities, challenges, and research agenda

AU - Direskeneli, Haner

AU - Aydin, Sibel Z.

AU - Kermani, Tanaz A.

AU - Matteson, Eric L.

AU - Boers, Maarten

AU - Herlyn, Karen

AU - Luqmani, Raashid A.

AU - Neogi, Tuhina

AU - Seo, Philip

AU - Suppiah, Ravi

AU - Tomasson, Gunnar

AU - Merkel, Peter A.

PY - 2011/7

Y1 - 2011/7

N2 - Giant cell (GCA) and Takayasu's arteritis (TAK) are 2 forms of large-vessel vasculitis (LVV) that involve the aorta and its major branches. GCA has a predilection for the cranial branches, while TAK tends to affect the extracranial branches. Both disorders may also cause nonspecific constitutional symptoms. Although some clinical features are more common in one or the other disorder and the ages of initial presentation differ substantially, there is enough clinical and histopathologic overlap between these disorders that some investigators suggest GCA and TAK may be 2 processes within the spectrum of a single disease. There have been few randomized therapeutic trials completed in GCA, and none in TAK. The lack of therapeutic trials in LVV is only partially explained by the rarity of these diseases. It is likely that the lack of well validated outcome measures for LVV and uncertainties regarding trial design contribute to the paucity of trials for these diseases. An initiative to develop a core set of outcome measures for use in clinical trials of LVV was launched by the international OMERACT Vasculitis Working Group in 2009 and subsequently endorsed by the OMERACT community at the OMERACT 10 meeting. Aims of this initiative include: (1) to review the literature and existing data related to outcome assessments in LVV; (2) to obtain the opinion of experts and patients on disease content; and (3) to formulate a research agenda to facilitate a more data-based approach to outcomes development. The Journal of Rheumatology

AB - Giant cell (GCA) and Takayasu's arteritis (TAK) are 2 forms of large-vessel vasculitis (LVV) that involve the aorta and its major branches. GCA has a predilection for the cranial branches, while TAK tends to affect the extracranial branches. Both disorders may also cause nonspecific constitutional symptoms. Although some clinical features are more common in one or the other disorder and the ages of initial presentation differ substantially, there is enough clinical and histopathologic overlap between these disorders that some investigators suggest GCA and TAK may be 2 processes within the spectrum of a single disease. There have been few randomized therapeutic trials completed in GCA, and none in TAK. The lack of therapeutic trials in LVV is only partially explained by the rarity of these diseases. It is likely that the lack of well validated outcome measures for LVV and uncertainties regarding trial design contribute to the paucity of trials for these diseases. An initiative to develop a core set of outcome measures for use in clinical trials of LVV was launched by the international OMERACT Vasculitis Working Group in 2009 and subsequently endorsed by the OMERACT community at the OMERACT 10 meeting. Aims of this initiative include: (1) to review the literature and existing data related to outcome assessments in LVV; (2) to obtain the opinion of experts and patients on disease content; and (3) to formulate a research agenda to facilitate a more data-based approach to outcomes development. The Journal of Rheumatology

KW - Giant cell arteritis

KW - Outcomes

KW - Takayasu's arteritis

KW - Vasculitis

UR - http://www.scopus.com/inward/record.url?scp=79959972958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959972958&partnerID=8YFLogxK

U2 - 10.3899/jrheum.110275

DO - 10.3899/jrheum.110275

M3 - Article

C2 - 21724719

AN - SCOPUS:79959972958

VL - 38

SP - 1471

EP - 1479

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 7

ER -